JP2023533961A5 - - Google Patents
Info
- Publication number
- JP2023533961A5 JP2023533961A5 JP2023500997A JP2023500997A JP2023533961A5 JP 2023533961 A5 JP2023533961 A5 JP 2023533961A5 JP 2023500997 A JP2023500997 A JP 2023500997A JP 2023500997 A JP2023500997 A JP 2023500997A JP 2023533961 A5 JP2023533961 A5 JP 2023533961A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- pharmaceutical composition
- formula
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049556P | 2020-07-08 | 2020-07-08 | |
| US63/049,556 | 2020-07-08 | ||
| PCT/US2021/040736 WO2022011043A2 (en) | 2020-07-08 | 2021-07-07 | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533961A JP2023533961A (ja) | 2023-08-07 |
| JP2023533961A5 true JP2023533961A5 (https=) | 2025-02-20 |
Family
ID=79553738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500997A Pending JP2023533961A (ja) | 2020-07-08 | 2021-07-07 | 線維性疾患およびがんを処置するための化合物、組成物、および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230248835A1 (https=) |
| EP (1) | EP4178574A4 (https=) |
| JP (1) | JP2023533961A (https=) |
| CN (1) | CN115916342A (https=) |
| AU (1) | AU2021305193A1 (https=) |
| CA (1) | CA3184740A1 (https=) |
| WO (1) | WO2022011043A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3996715A4 (en) * | 2019-07-08 | 2024-01-03 | Purdue Research Foundation | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING FIBROTIC DISEASES AND CANCER |
| EP4271378A4 (en) * | 2021-01-04 | 2026-03-11 | Purdue Research Foundation | METHODS FOR IMPROVING MODIFIED CELL THERAPIES IN CANCER TREATMENT |
| EP4683669A2 (en) * | 2023-03-23 | 2026-01-28 | Purdue Research Foundation | Combinations and methods for enhancing checkpoint inhibitor therapies in cancer treatment |
| CN119215159A (zh) * | 2024-09-24 | 2024-12-31 | 深圳市格茵莱生物科技有限公司 | 树突状细胞多抗原负载免疫治疗方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0413558A (pt) * | 2003-08-12 | 2006-10-17 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por hidroxilamina |
| CA2547020C (en) * | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
| EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
| WO2005094531A2 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| JP2007530579A (ja) * | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン |
| EP1851224A2 (en) * | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
| HRP20120895T1 (hr) * | 2007-05-08 | 2012-11-30 | Astrazeneca Ab | Imidazokinolini sa imuno-modulacijskim svojstvima |
| KR102685007B1 (ko) * | 2015-08-31 | 2024-07-12 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 구아니딘 치환된 이미다조[4,5-c] 고리 화합물 |
| DE212016000029U1 (de) * | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| AU2017271550B2 (en) * | 2016-05-25 | 2023-11-02 | Endocyte, Inc. | Method of treating cancer by targeting myeloid-derived suppressor cells |
| BR112020004505A2 (pt) * | 2017-09-06 | 2020-09-15 | BioNTech SE | imidazoquinolinas substituídas como agonistas de tlr7 |
| WO2020023680A1 (en) * | 2018-07-24 | 2020-01-30 | Torque Therapeutics, Inc. | Tlr7/8 agonists and liposome compositions |
| AU2019335366A1 (en) * | 2018-09-07 | 2021-03-25 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
| CA3125133A1 (en) * | 2018-12-26 | 2020-07-02 | Birdie Biopharmaceuticals, Inc. | Immune modulatory combinations and methods for treating cancers |
| WO2020236253A1 (en) * | 2019-05-20 | 2020-11-26 | Massachusetts Institute Of Technology | Boronic ester prodrugs and uses thereof |
-
2021
- 2021-07-07 US US18/004,656 patent/US20230248835A1/en active Pending
- 2021-07-07 JP JP2023500997A patent/JP2023533961A/ja active Pending
- 2021-07-07 WO PCT/US2021/040736 patent/WO2022011043A2/en not_active Ceased
- 2021-07-07 CA CA3184740A patent/CA3184740A1/en active Pending
- 2021-07-07 EP EP21837283.7A patent/EP4178574A4/en active Pending
- 2021-07-07 AU AU2021305193A patent/AU2021305193A1/en active Pending
- 2021-07-07 CN CN202180051458.8A patent/CN115916342A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533961A5 (https=) | ||
| TW557212B (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
| ES2211206T3 (es) | Derivados de cochinol como agentes de deterioro vascular. | |
| EP2061749B1 (en) | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate | |
| CN101595217A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的1H-咪唑并[4,5-c]喹啉-4-胺类及其相关化合物的前药 | |
| JP2010501584A5 (https=) | ||
| EA011074B1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| JP2011529048A5 (https=) | ||
| ES2444550T3 (es) | Arilpropenamidas y heteroarilpropenamidas, derivados de las mismas y usos terapéuticos de las mismas | |
| US9713597B2 (en) | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| JP2021530554A5 (https=) | ||
| JP5378221B2 (ja) | 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ | |
| ES2928666T3 (es) | Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas | |
| HK1203188A1 (en) | Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates | |
| EP0774257B1 (en) | Use of piperazine and homopiperazine compounds for the inhibition of cellular adhesion and infiltration | |
| CN117242049A (zh) | 6-羟基-大麻二酚-c4 | |
| ES2349471T3 (es) | Derivados de azabiciclooctan-3-ona y su uso. | |
| ES3038469T3 (en) | Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy | |
| EP2405751B1 (en) | Sphingosine kinase inhibitor prodrugs | |
| EP2117552B1 (en) | Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases | |
| JP7396991B2 (ja) | 癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン－１，３－ジオン及びイソインドールプロドラッグの組成物 | |
| WO1999056550A1 (en) | Method for treating migraine in mammals | |
| US20210212966A1 (en) | Prodrug for therapeutic applications | |
| CN106946851B (zh) | 一种用于预防和治疗肾结石的药物 |